CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase II Study of IL-5-receptor-alpha-chain (IL-5Rα) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT04552288
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:29:10.205734+00:00
- Published At
- 2025-04-29T00:00:00+00:00
- Record Updated At
- 2026-04-16
- Results Posted At
- 2025-04-29
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Solid Tumor", "Solid Carcinoma", "Solid Tumor, Adult", "Hematologic Malignancy"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-04-16"- protocolSection.identificationModule.nctId
"NCT04552288"- protocolSection.identificationModule.officialTitle
"Phase II Study of IL-5-receptor-alpha-chain (IL-5R\u03b1) Inhibition With Benralizumab for Eosinophil-Related Cutaneous Adverse Events in Cancer Patients"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE2"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
"2025-04-29"
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.